Despite evidence that mutations in RAS genes, particularly KRAS, play an essential role in predicting resistance to anti-EGFR therapy and worse prognosis in CRC patients, only a few studies have investigated the clinical value of mutations in exons 3 and 4. The gene discussed is KRAS; the disease is colorectal carcinoma.